Oral semaglutide uptake reached injection levels within ten weeks of approval

Early oral semaglutide uptake for weight management was fast, according to a research letter in JAMA Network Open. Using health records from Epic Cosmos, a University of Pennsylvania team found that new prescriptions of the Wegovy pill climbed from almost nothing to a weekly peak within ten weeks of the December 2025 FDA approval, briefly passing new starts on injectable semaglutide. Tirzepatide stayed ahead throughout. The molecule does not move on our board; it was already approved. What the study adds is a first population level view of how quickly a daily peptide pill found its place.

How the Epic Cosmos study counted new starts

The authors, Yuqing Lei, Huilin Tang, Xinyao Jian, David Asch and Yong Chen, used deidentified records from Epic Cosmos, a data network the paper describes as holding more than 300 million patient records from over 2,000 hospitals and 47,100 clinics. They selected adults who qualified for obesity drugs: a body mass index of at least 30, or at least 27 with a weight related condition such as high blood pressure or sleep apnoea. People with type 2 diabetes, or without a recorded body mass index, were left out. That left 47,894,786 eligible adults. A new start meant a first prescription of a drug with none for the same drug in the previous year, counted weekly from 22 December 2025 to 15 March 2026.

Three drugs were tracked side by side: oral semaglutide, injectable semaglutide and injectable tirzepatide. Over the twelve week window, 148,792 eligible adults started oral semaglutide, against 227,040 who started the semaglutide injection and 355,513 who started tirzepatide. Of the oral starts, 130,312 were for the Wegovy pill and 18,480 for Rybelsus, the older diabetes tablet, even though the cohort excluded people with diabetes. The outcome was simple: weekly new starts per 10,000 eligible adults. The design is descriptive. It counts prescriptions written inside participating health systems and does not try to explain why clinicians chose one drug over another, which matters when reading the numbers that follow.

Oral semaglutide uptake peaked in week ten

Oral semaglutide uptake rose almost from zero to a peak of 4.56 new starts per 10,000 eligible adults in week ten, the week of 2 to 8 March 2026, with a 95 percent confidence interval of 4.50 to 4.62. At that point it had caught up with, and for a short time exceeded, the weekly rate for injectable semaglutide. Tirzepatide had the highest weekly rate in every week of the study. Among adults with no GLP 1 drug in the prior year, the pattern looked similar, but the pill stayed below the semaglutide injection. So the early surge was not only new patients, and the switch from injections explains part of the curve.

At that point it had caught up with, and for a short time exceeded, the weekly rate for injectable semaglutide.

The table sets out how the three groups of new starters compared. Pill users were a little older, more often women, slightly lighter on average and more often covered by Medicare than people starting either injection. Family medicine clinicians wrote about half of the first prescriptions for each of the three drugs, so the pill was not confined to specialist obesity clinics. The authors suggest that tirzepatide's lead may reflect its larger weight loss and longer track record. They also write that pills, among them orforglipron, which gained approval in April 2026, may ease some barriers tied to injections. That is a hypothesis, and this study was not designed to test it.

New users and switchers on the Wegovy pill

Just over half of the oral starters, 53.0 percent, had used no GLP 1 drug in the previous twelve months. The rest were mostly switching. Prior injectable semaglutide was recorded for 28.9 percent of all oral starters, and prior tirzepatide for 27.5 percent. The authors read this as early uptake reflecting "both expansion to new users and switching from existing GLP-1 RA therapies." For the Wegovy pill, that split matters commercially and clinically. A drug that mostly converts existing injection users changes the form of treatment more than its reach. One that draws in people who never started an injection widens the treated population, and here the data show a roughly even mix of the two.

The approval behind these numbers came on 22 December 2025, when the FDA cleared a once daily oral semaglutide tablet for weight management, the first oral GLP 1 drug for that use, according to Novo Nordisk's approval release. The company said the label also covers lowering the risk of major cardiovascular events. In the 64 week phase 3b OASIS 4 trial, which enrolled 307 adults living with obesity or overweight plus at least one related illness, people who kept taking the tablet lost 16.6 percent of body weight on average, and about one in three lost a fifth or more. Novo had said it expected a US launch in early January 2026.

What the uptake data cannot show

The authors list several limits that a careful reader should keep in mind. The records do not state why a drug was prescribed, although dropping people with diabetes reduces that problem. A prescription is not proof the drug was dispensed or taken. Prescriptions written outside participating Epic systems, including online and direct to consumer services, may be missing from the counts entirely. Data delays may have cut off some early starts. And because the analysis was purely descriptive, it made no adjustment for confounding factors at all. The full research letter closes by asking for longer studies of persistence, adherence and outcomes in routine practice.

Those gaps shape how the board should read the result. Fast early prescribing tells us that many clinicians and patients wanted an oral option once it existed. It says nothing yet about how long people stay on the tablet, or how real world weight loss compares with the trial. Persistence is the next number to watch, since a daily tablet asks for a different routine than a weekly injection does. Our earlier story on the orforglipron and oral semaglutide comparison covers the rival pill. The full set of approved and pipeline drugs sits on our incretins class page, where new readouts will appear.

Conclusion

Oral semaglutide uptake in its first twelve weeks was quick, peaking in week ten and briefly matching the semaglutide injection, while tirzepatide stayed ahead throughout. About half of the new users were new to GLP 1 treatment. The data are descriptive and count prescriptions, not use. The next checkpoint is evidence on persistence and outcomes in routine practice. This story is research news, not medical advice.